HSBC Holdings’s Matinas BioPharma MTNB Stock Holding History

HSBC Holdings’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-32	Closed	-$67K	–	2239
2017 Q1	$67K	Buy	+32	New	+$78.3K	﹤0.01%	2077

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AWMG

Alliance Wealth Management Group Flemington, New Jersey $514M AUM 16.05% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

HSBC Holdings's MTNB Position: Q2 2017 in Review

HSBC Holdings sold out of Matinas BioPharma (MTNB) in Q2 2017, closing a stake of 32 shares — an estimated $67K sold.

HSBC Holdings first reported a position in MTNB in Q1 2017 and held it in 1 quarter. The position peaked at $67K in Q1 2017. 44 funds tracked by Wall St. Rank hold MTNB as of Q2 2017.

HSBC Holdings reported no remaining Matinas BioPharma position as of Q2 2017 after selling out during the quarter.
HSBC Holdings sold 32 Matinas BioPharma shares in Q2 2017, an estimated $67K.
HSBC Holdings first reported a position in Matinas BioPharma in Q1 2017 and held it in 1 quarter.
HSBC Holdings's Matinas BioPharma position peaked at $67K in Q1 2017.
44 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2017.

Based on HSBC Holdings's 13F filing for Q2 2017, filed 14 Aug 2017.